TY - JOUR
T1 - High risk of bloodstream infections, diverse causal pathogens, and association with haemodialysis and plasma exchange in ANCA-associated vasculitis
AU - Bruun, Nanna Thuesen
AU - Kofod, Dea H
AU - Carlson, Nicholas
AU - Hornum, Mads
AU - Fosbøl, Emil L
AU - Østergaard, Lauge
AU - Volstedlund, Marianne
AU - Finsen, Stine H
AU - Moser, Claus
AU - Rydahl, Casper
AU - Ivarsen, Per
AU - Gregersen, Jon Waarst
AU - Egfjord, Martin
AU - Szpirt, Wladimir M
AU - Nelveg-Kristensen, Karl Emil
AU - Danish Vasculitis Association (DANVAS)
N1 - © The Author(s) 2025. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For commercial re-use, please contact [email protected] for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site—for further information please contact [email protected].
PY - 2025/12/1
Y1 - 2025/12/1
N2 - OBJECTIVES: Infections from immunosuppressive treatment are a major cause of hospitalization and mortality in ANCA-associated vasculitis (AAV). This study examines bloodstream infections (BSIs) in incident AAV patients, comparing incidence, bacterial distribution and risk to the general population, with emphasis on central venous catheters (CVCs).METHODS: Using Danish nationwide registries, we studied patients diagnosed from 2010 to 2018, followed until first BSI, death or a maximum of 5 years. Controls were matched 1:4 by age and sex. Cumulative incidence was estimated using Aalen-Johansen, and adjusted Cox regression modelled survival time.RESULTS: A total of 111 BSIs were identified in 80 (8.5%) of 937 AAV patients, compared with 65 BSIs in 58 (1.7%) of 3476 controls. The incidence of BSIs was significantly higher in AAV patients (34.5/1000 person-years against 4.8/1000 person-years). One-year hazard ratio (HR) for first-time BSIs was significantly elevated in AAV patients (HR 10.5, [95% CI 5.58-11.9]), and those receiving haemodialysis (HR 34.8, 95% CI 3.35-360.8) or plasma exchange (HR 14.6, 95% CI 3.79-56.6) faced even higher infection rates. Following first-time BSI, one-year mortality rates were equally high in AAV patients (36.3%) and controls (34.5%). Most common microbial agents-Escherichia coli, Staphylococcus aureus, enterococci and streptococci-were similar between the two groups. However, AAV patients exhibited higher microbial diversity, with 48.6% attributed to other pathogens like coagulase-negative staphylococci, Klebsiella pneumoniae, Pseudomonas aeruginosa and fungi.CONCLUSION: AAV patients face high BSI risk, diverse microbiology and increased one-year mortality, with CVC-related interventions as solitary risk factors.
AB - OBJECTIVES: Infections from immunosuppressive treatment are a major cause of hospitalization and mortality in ANCA-associated vasculitis (AAV). This study examines bloodstream infections (BSIs) in incident AAV patients, comparing incidence, bacterial distribution and risk to the general population, with emphasis on central venous catheters (CVCs).METHODS: Using Danish nationwide registries, we studied patients diagnosed from 2010 to 2018, followed until first BSI, death or a maximum of 5 years. Controls were matched 1:4 by age and sex. Cumulative incidence was estimated using Aalen-Johansen, and adjusted Cox regression modelled survival time.RESULTS: A total of 111 BSIs were identified in 80 (8.5%) of 937 AAV patients, compared with 65 BSIs in 58 (1.7%) of 3476 controls. The incidence of BSIs was significantly higher in AAV patients (34.5/1000 person-years against 4.8/1000 person-years). One-year hazard ratio (HR) for first-time BSIs was significantly elevated in AAV patients (HR 10.5, [95% CI 5.58-11.9]), and those receiving haemodialysis (HR 34.8, 95% CI 3.35-360.8) or plasma exchange (HR 14.6, 95% CI 3.79-56.6) faced even higher infection rates. Following first-time BSI, one-year mortality rates were equally high in AAV patients (36.3%) and controls (34.5%). Most common microbial agents-Escherichia coli, Staphylococcus aureus, enterococci and streptococci-were similar between the two groups. However, AAV patients exhibited higher microbial diversity, with 48.6% attributed to other pathogens like coagulase-negative staphylococci, Klebsiella pneumoniae, Pseudomonas aeruginosa and fungi.CONCLUSION: AAV patients face high BSI risk, diverse microbiology and increased one-year mortality, with CVC-related interventions as solitary risk factors.
KW - Humans
KW - Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis/therapy
KW - Male
KW - Female
KW - Renal Dialysis/adverse effects
KW - Middle Aged
KW - Denmark/epidemiology
KW - Aged
KW - Plasma Exchange/adverse effects
KW - Incidence
KW - Registries
KW - Risk Factors
KW - Adult
KW - Bacteremia/epidemiology
KW - Immunosuppressive Agents/adverse effects
KW - Sepsis/epidemiology
KW - Case-Control Studies
KW - central venous catheters
KW - haemodialysis
KW - ANCA-associated vasculitis
KW - bloodstream infections
KW - microbial aetiology
KW - plasma exchange
UR - https://www.scopus.com/pages/publications/105023648248
U2 - 10.1093/rheumatology/keaf438
DO - 10.1093/rheumatology/keaf438
M3 - Journal article
C2 - 40828891
SN - 1462-0332
VL - 64
SP - 6328
EP - 6336
JO - Rheumatology (Oxford, England)
JF - Rheumatology (Oxford, England)
IS - 12
ER -